Phase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis

Clinical Trial

NCT05384249 Recruiting, Active

A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Non-infectious, Intermediate-, Posterior- or Pan-uveitis

Phase 2

Interventional

Disease

Disease type

Uveitis

Orphan drug recognition

Yes

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

23/08/2022

Closing date

31/10/2024

Inclusion criteria :

Exclusion criteria :

Funding

private

Members involved

Others investigators

Pr Andreas Wedrich

Representative

Austria

Pr Petra Liskova

Representative

Czech Republic

Anterior Segment Rare Eye Diseases (WG4), Genetic Diagnostics (TWG6), National Integration (TWG9), Neuro-Ophthalmology Rare Diseases (WG2), Pediatric Ophthalmology Rare Diseases (WG3), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Working Group Leader

Pr Paul Friedemann

Representative

Germany

Neuro-Ophthalmology Rare Diseases (WG2), Registries & Epidemiology (TWG7), Research (TWG8)

Pr Frank Holz

Representative

Germany

Dr Philipp Herrmann

Substitute

Germany

CPMS & Digital Medecine (TWG10), Genetic Diagnostics (TWG6), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Pr Martin Spitzer

Representative

Germany

Pediatric Ophthalmology Rare Diseases (WG3), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Dr Johannes Birtel

Substitute

Germany

CPMS & Digital Medecine (TWG10), Genetic Diagnostics (TWG6), Pediatric Ophthalmology Rare Diseases (WG3), Research (TWG8), Retinal Rare Eye Diseases (WG1)